18-24 patients will be included in the clinical Phase I/II study. Results from the Phase I part are expected in first half of 2013. The study will include operable patients, and will run at the Radium Hospital at Oslo University Hospital, international pioneers in development of immunotherapy and cancer vaccines.
Approx 80-90% of pancreatic cancers have RAS mutations. Cancers with RAS mutations have proved to be difficult to treat with current treatment, and there is a significant unmet medical need.
TG01 has already shown promising results in patients. A follow-up review of clinical trials from the end of the 90’es indicates increased survival for patients treated with TG01.
Targovax owns patents and the documentation from earlier development of TG01. TG01 has received Orphan Drug Status for Pancreatic Cancer in EU and USA.
Press release (Norwegian/English)
Targovax Press Release PR Newswire: (English), (French), (German)
Clinical study: (in Norwegian, OUS Radiumhospitalet), (in English, Nordic NECT)